Amopyroquin (Propoquin) in rheumatoid arthritis

A controlled, double-blind trial of amopyroquin vs. placebo has been completed in 15 patients with active, classical or definite rheumatoid arthritis. Improvement in all the parameters determined occurred while the patients were on amopyroquin. Grip strength, sedimentation rate, and Lansbury's indices showed statistically significant improvement while on amopyroquin. Improvement in the 50-foot walk and A.R.A. functional capacity approached statistical significance. Amopyroquin was well tolerated, but asymptomatic elevation of SGOT occurred in four patients and appeared to be related to the drug. Other tests of liver function remained normal.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/37697/1/1780060406_ftp.pd